Levetiracetam Al (Levetiracetam)

Levetiracetam works by binding to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding modulates calcium‑dependent exocytosis, stabilizing neuronal firing and decreasing the hyper‑excitability that leads to seizure activity.

The dosage of levetiracetam is individualized and set by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. The prescriber determines the appropriate strength and dosing schedule for each patient.

Data on levetiracetam use during pregnancy and lactation are limited. Clinicians must weigh the potential benefits of seizure control against any possible risks to the fetus or infant. A risk‑benefit assessment should be performed, and alternative therapies considered when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Levetiracetam offers a broad spectrum of seizure control with a relatively favorable drug‑interaction profile compared with enzyme‑inducing agents such as carbamazepine or phenytoin. It does not require routine therapeutic drug monitoring, but clinicians should still assess individual patient response and tolerability relative to alternatives.

Levetiracetam tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Do not store in areas with high humidity or extreme heat.

Levetiracetam Al is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and any specific administration requirements.

Serious risks include severe allergic reactions such as Stevens‑Johnson syndrome, blood dyscrasias, marked mood changes including depression or suicidal thoughts, and rare cases of rhabdomyolysis. Patients should be monitored closely for any of these symptoms and seek medical attention promptly if they occur.

Levetiracetam should be avoided in individuals with known hypersensitivity to the drug or its excipients. Patients with severe renal impairment must have dose adjustments, and those with uncontrolled psychiatric conditions may require careful monitoring before initiating therapy.